INDOCO
Indoco Remedies Limited (INDOCO) Stock Analysis
Indoco Remedies Limited develops, manufactures, and markets pharmaceutical formulations for domestic and export markets. It has branded generics in pain, cough, and primary care therapies. The company runs API and formulation facilities in India. It is a listed mid-tier pharma company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹230.70
-8.36% 1W | -14.20% 52W
Market Cap
2.1k CR
P/E Ratio
699.1
52W High
₹317.4
52W Low
₹162.2
Div. Yield
0.08%
Beta
0.6
50 DMA
₹240.4
200 DMA
₹221.2
Profit Margin
0.3%
Inst. Own.
17.7%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 426 | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 440 | 485 | 445 | 476 | 468 |
| Expenses | 365 | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 422 | 442 | 414 | 426 | 426 |
| Operating Profit | 61 | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 | 43 | 32 | 50 | 41 |
| OPM % | 14% | 15% | 14% | 11% | 11% | 9% | 2.9% | -0.2% | 4.0% | 9% | 7% | 10% | 9% |
| Other Income | 0 | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 | 0 | -5 | 4 | 100 |
| Interest | 8 | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 | 25 | 26 | 46 | 28 |
| Depreciation | 20 | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 | 32 | 32 | 32 | 35 |
| Profit before tax | 34 | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 | -14 | -31 | -25 | 78 |
| Tax % | 29% | 24% | 31% | 33% | 74% | 107% | -8% | -9% | -1% | -32% | -6% | -5% | 16% |
| Net Profit | 24 | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 | -9 | -29 | -24 | 65 |
| EPS in Rs | 2.65 | 3.81 | 1.77 | 2.46 | 0.28 | -1.04 | -2.86 | -4.38 | -3.88 | -0.86 | -3.23 | -2.34 | 7.04 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 | 1,873 |
| Expenses | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,565 | 1,703 | 1,708 |
| Operating Profit | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 142 | 165 |
| OPM % | 19% | 17% | 15% | 13% | 8% | 11% | 18% | 21% | 17% | 13% | 6% | 8% | 9% |
| Other Income | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | -0 | 98 |
| Interest | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 122 | 124 |
| Depreciation | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 126 | 131 |
| Profit before tax | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -106 | 8 |
| Tax % | 24% | 17% | 15% | 15% | -69% | 16% | 30% | 35% | 26% | 29% | 5% | -7% | |
| Net Profit | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -99 | 3 |
| EPS in Rs | 8.99 | 8.89 | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | -7.99 | -10.31 | 0.61 |
| Dividend Payout % | 18% | 18% | 19% | 22% | -95% | 11% | 15% | 13% | 15% | 14% | -2% | -2% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 3.0% | 8.0% | 6.0% |
Shareholding Pattern
Promoters58.90%
FIIs1.22%
DIIs18.96%
Public20.82%
Promoters58.90%
FIIs1.25%
DIIs18.16%
Public21.60%
Promoters58.90%
FIIs1.10%
DIIs18.15%
Public21.76%
Promoters58.86%
FIIs0.94%
DIIs18.15%
Public21.90%
Promoters58.86%
FIIs1.27%
DIIs17.68%
Public22.04%
Promoters58.69%
FIIs1.55%
DIIs18.06%
Public21.69%
Promoters58.72%
FIIs1.92%
DIIs19.41%
Public19.92%
Promoters58.90%
FIIs1.24%
DIIs18.75%
Public21.02%
Promoters58.86%
FIIs0.94%
DIIs18.15%
Public21.90%
Promoters58.86%
FIIs1.27%
DIIs17.68%
Public22.04%
INDOCO
Holdings Analysis
Key strengths & risk signals
54
Overall
40
Fundamental
68
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (230.7) above 200-day but below 50-day.
WEAK YEAR! Stock declined 14.2% in the last year.
NEGATIVE MOMENTUM! Price declined across timeframes - down 8.4% (1 week), 0.1% (1 month), 11.3% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (240.4) is above 200-day average (221.2) - positive signal.
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 4,333,699 vs down days: 346,960. Ratio: 12.49x
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Fundamental & Technical Analysis
54Overall
40Fundamental
68Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.0% (SLOW, 5/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 0.3% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.08% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 21.75% public ownership - balanced ownership structure.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 4 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (240.4) is above 200-day average (221.2) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (230.7) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
2/10
WEAK YEAR! Stock declined 14.2% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 4,333,699 vs down days: 346,960. Ratio: 12.49x
RSI
3/5
NEUTRAL! RSI at 40.9 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 44.1% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 8.4% (1 week), 0.1% (1 month), 11.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
INDOCO
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-04 | Concall PDF | |
| Q4FY262026-05-11 | Concall PDF | |
| Q3FY262026-02-09 | Concall PDF | |
| Q2FY262025-11-10 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDOCO | ₹230.70 | 699.1 | 0.3% | 3.0% | – | -14.2% | 54 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| SAKAR | ₹1,011.50 | 72.3 | 13.3% | 22.0% | 23.0% | +184.6% | 78 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹23.30 | 24.8 | 17.2% | 29.4% | 56.2% | +38.7% | 84 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| WINDLAS | ₹949.20 | 30.4 | 7.1% | 20.7% | 16.0% | +11.7% | 75 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| BETA | ₹1,950.20 | 28.7 | 11.1% | 19.2% | 10.5% | +13.7% | 67 | APPROACHING SUPPORT | +35.0% | +75.6% | +25.2% | +33.5% |
| HESTERBIO | ₹2,058.70 | 12.8 | 41.6% | 7.7% | 27.8% | +24.4% | 76 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
Data from TradeAlone · Updated daily
